$11.32
2.50% yesterday
NYSE, May 14, 09:48 pm CET
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Zymeworks Inc. Stock price

$11.25
+0.25 2.27% 1M
-5.01 30.81% 6M
-3.39 23.16% YTD
+2.25 25.00% 1Y
+5.91 110.67% 3Y
-25.48 69.37% 5Y
-1.75 13.46% 10Y
NYSE, Closing price Wed, May 14 2025
-0.36 3.10%
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Key metrics

Market capitalization $790.35m
Enterprise Value $543.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.82
P/S ratio (TTM) P/S ratio 8.46
P/B ratio (TTM) P/B ratio 2.43
Revenue growth (TTM) Revenue growth 85.05%
Revenue (TTM) Revenue $93.38m
EBIT (operating result TTM) EBIT $-107.63m
Free Cash Flow (TTM) Free Cash Flow $-75.32m
Cash position $265.29m
EPS (TTM) EPS $-1.50
P/E forward negative
P/S forward 7.87
EV/Sales forward 5.41
Short interest 12.34%
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Zymeworks Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Zymeworks Inc. forecast:

Buy
78%
Hold
22%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
93 93
85% 85%
100%
- Direct Costs 12 12
27% 27%
13%
81 81
141% 141%
87%
- Selling and Administrative Expenses 38 38
7% 7%
41%
- Research and Development Expense 138 138
7% 7%
148%
-95 -95
28% 28%
-102%
- Depreciation and Amortization 12 12
27% 27%
13%
EBIT (Operating Income) EBIT -108 -108
28% 28%
-115%
Net Profit -114 -114
10% 10%
-122%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore - Chief Scientific Officer Leone Patterson - Executive Vice President, Chief Business and Financial Officer Conference Call Participants Charles Zhu - LifeSci Capital Brian Cheng - JPM Stephen Will...
Neutral
GlobeNewsWire
7 days ago
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three months ended March 31, 20...
Positive
Seeking Alpha
17 days ago
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER2+ BTC and multiple ongoing trials in high-value indications. Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 286
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today